STOCK TITAN

Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Inspira Technologies (Nasdaq: IINN) has signed a distribution agreement with Glo-Med Networks to serve as its primary distributor in the United States. The agreement establishes a Florida-based distribution facility that will support the deployment of the INSPIRA ART100, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The facility will provide customer support and after-market services through a partnership with Med-Stat Consulting Services. This strategic move aims to enhance operational efficiency for the planned 2024 deployment of the ART100 and future products. The company's flagship product, INSPIRA ART, targets a potential $19 billion market opportunity, aiming to serve 20 million acute respiratory failure patients annually.

Inspira Technologies (Nasdaq: IINN) ha firmato un accordo di distribuzione con Glo-Med Networks per fungere da distributore principale negli Stati Uniti. L'accordo prevede l'istituzione di una struttura di distribuzione in Florida che supporterà il lancio dell'INSPIRA ART100, che ha ottenuto la certificazione FDA 510(k) per le procedure di bypass cardiopolmonare. La struttura fornirà supporto ai clienti e servizi post-vendita attraverso una partnership con Med-Stat Consulting Services. Questo passo strategico mira a migliorare l'efficienza operativa per il lancio previsto nel 2024 dell'ART100 e dei futuri prodotti. Il prodotto di punta dell'azienda, INSPIRA ART, punta a un'opportunità di mercato potenziale di 19 miliardi di dollari, con l'obiettivo di servire annualmente 20 milioni di pazienti con insufficienza respiratoria acuta.

Inspira Technologies (Nasdaq: IINN) ha firmado un acuerdo de distribución con Glo-Med Networks para actuar como su distribuidor principal en los Estados Unidos. El acuerdo establece una instalación de distribución con sede en Florida que apoyará el lanzamiento del INSPIRA ART100, que ha recibido la aprobación 510(k) de la FDA para procedimientos de bypass cardiopulmonar. La instalación proporcionará soporte al cliente y servicios postventa a través de una colaboración con Med-Stat Consulting Services. Este movimiento estratégico tiene como objetivo mejorar la eficiencia operativa para el lanzamiento planeado en 2024 del ART100 y futuros productos. El producto insignia de la empresa, INSPIRA ART, apunta a una oportunidad de mercado potencial de 19 mil millones de dólares, con el objetivo de atender a 20 millones de pacientes con falla respiratoria aguda anualmente.

Inspira Technologies (Nasdaq: IINN)은 Glo-Med Networks와 미국 내 주요 유통업체로서의 배급 계약을 체결했습니다. 이 계약에는 심폐 우회 수술을 위한 FDA 510(k) 승인을 받은 INSPIRA ART100의 배급을 지원할 플로리다 기반의 배급 시설이 설립됩니다. 이 시설은 Med-Stat Consulting Services와의 협업을 통해 고객 지원 및 애프터 마켓 서비스를 제공할 것입니다. 이 전략적 조치는 2024년 ART100 및 향후 제품의 배급을 위한 운영 효율성을 향상시키기 위한 것입니다. 회사의 주력 제품인 INSPIRA ART는 190억 달러의 잠재적 시장 기회를 목표로 하여 매년 2천만 명의 급성 호흡 부전 환자를 서비스할 계획입니다.

Inspira Technologies (Nasdaq: IINN) a signé un accord de distribution avec Glo-Med Networks pour devenir son distributeur principal aux États-Unis. L'accord établit une installation de distribution basée en Floride qui soutiendra le déploiement de l'INSPIRA ART100, qui a reçu l'approbation FDA 510(k) pour les procédures de contournement cardiopulmonaire. L'installation fournira un support client et des services après-vente grâce à un partenariat avec Med-Stat Consulting Services. Ce mouvement stratégique vise à améliorer l'efficacité opérationnelle pour le déploiement prévu de l'ART100 en 2024 et pour de futurs produits. Le produit phare de l'entreprise, INSPIRA ART, cible une opportunité de marché potentielle de 19 milliards de dollars, visant à servir 20 millions de patients atteints d'insuffisance respiratoire aiguë chaque année.

Inspira Technologies (Nasdaq: IINN) hat einen Vertriebsvertrag mit Glo-Med Networks unterzeichnet, um als Hauptdistributor in den Vereinigten Staaten zu fungieren. Der Vertrag sieht die Einrichtung einer Vertriebsstelle in Florida vor, die die Einführung des INSPIRA ART100 unterstützen wird, das die FDA 510(k)-Zulassung für kardiopulmonale Bypass-Verfahren erhalten hat. Die Einrichtung wird Kundenunterstützung und After-Sales-Services in Partnerschaft mit Med-Stat Consulting Services anbieten. Dieser strategische Schritt zielt darauf ab, die betriebliche Effizienz für die geplante Einführung des ART100 im Jahr 2024 und zukünftige Produkte zu verbessern. Das Flaggschiffprodukt des Unternehmens, INSPIRA ART, zielt auf eine potenzielle Marktchance von 19 Milliarden US-Dollar, mit dem Ziel, jährlich 20 Millionen Patienten mit akuter Atemwegserkrankung zu betreuen.

Positive
  • FDA 510(k) clearance obtained for INSPIRA ART100
  • Established U.S. distribution infrastructure through Glo-Med partnership
  • Large market opportunity estimated at $19 billion
  • Target market of 20 million patients annually
Negative
  • Products still in development phase without regulatory approval (INSPIRA ART500, Cardi-ART, VORTX, HYLA)
  • Core flagship product (INSPIRA ART) not yet tested in humans

Insights

This distribution agreement marks a significant strategic move for Inspira Technologies. The establishment of a Florida-based distribution center through Glo-Med Networks represents a important operational milestone for the $19 billion market opportunity. The partnership with Med-Stat for biomedical engineering services adds credibility and infrastructure support.

The INSPIRA ART100's FDA 510(k) clearance for Cardiopulmonary Bypass procedures provides an initial market entry point, while the company positions itself for the broader deployment of its flagship INSPIRA ART device. The target market of 20 million acute respiratory failure patients annually presents substantial revenue potential.

The vertically integrated distribution and service model should enhance market penetration capabilities and customer support efficiency. However, investors should note that several key products, including the INSPIRA ART500 and HYLA blood sensor, are still in development and await regulatory approvals.

The distribution agreement demonstrates strong supply chain optimization strategy. Centralizing U.S. operations through a Florida-based facility offers several advantages:

  • Reduced logistics complexity and costs
  • Faster response times for customer support
  • Streamlined maintenance services through Med-Stat partnership
  • Enhanced inventory management capabilities
The integrated approach combining distribution, customer support and certified maintenance services creates operational synergies that could accelerate market penetration and improve customer satisfaction. This infrastructure development is particularly timely given the planned 2024 deployment of the INSPIRA ART100.

The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the U.S.

RA'ANANA, Israel, Oct. 24, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in the United States. The INSPIRA ART100 is U.S. Food and Drug Administration (FDA) 510(k)-cleared for Cardiopulmonary Bypass (CPB) procedures. Inspira aims to revolutionize life support for millions of acute respiratory failure patients each year with the Company's proprietary INSPIRA™ ART device being designed to monitor and elevate declining blood saturation levels in minutes without a mechanical ventilator. Targeting 20 million patients each year, the INSPIRA ART has a potential estimated $19 billion market opportunity. This agreement and distribution facility aims to enhance the Company's operational efficiency and customer service capabilities in the U.S. market. Toward the planned deployment of the INSPIRA ART100 in 2024 and looking ahead, the Company's goal is to introduce physicians and perfusionists to Inspira's technologies and brand proposition in preparation for the future planned deployment of the flagship INSPIRA ART.

Inspira Technologies Logo

 

The distribution facility, located in Florida, will play an important role in supporting the deployment and maintenance of the INSPIRA ART100 system and will potentially facilitate the commercialization of additional products in the U.S. market in the future. The medical distribution and service facility will be fully operated by Glo-Med and will serve as a central hub for Inspira's logistics operations, pursuant to the distribution agreement, ensuring the timely and efficient distribution of the Company's innovative medical devices. The facility will house a dedicated customer support team providing comprehensive support services to healthcare providers using Inspira's products. Additionally, the facility will provide original equipment manufacturer certified after-market services through a partnership with Med-Stat Consulting Services ("Med-Stat"), a reputable national biomedical engineering services firm. Med-Stat was founded in 2003 and provides onsite and depot medical equipment servicing for the largest and most reputable healthcare facilities in the U.S.

Joe Hayon, co-founder and President of Inspira Technologies, stated, "This distribution agreement represents a crucial milestone in our efforts to introduce Inspira's innovative technologies to the market. With Glo-Med managing the deployment and maintenance of the INSPIRA ART 100 system in the U.S., I believe that we are well-positioned for the future launch of our flagship INSPIRA ART and other products in our pipeline."

Matus Knoblich, CEO of Glo-Med, stated, "I believe that the coupling of Glo-Med's distribution network and capabilities with the industry leading service provided by Med-Stat will create a fully vertically integrated business model where customers can receive the highest level of service and support within the industry sector. Both companies will be working with the same mission in mind: growth and expansion of the Inspira Technologies brand coupled with a fully supported user experience. We believe that this will lead to success for all participants."

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilators, with patient being awake during treatment. The INSPIRA ART is being equipped with clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, and potentially supporting physicians in making informed decisions.

The Company's INSPIRA ART100 system has obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen Delivery System and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.

For more information, please visit our corporate website: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected benefits of the agreement with Glo-Med, the aims of the agreement, the potential benefits of the INSPIRA ART, the potential market size for the INSPIRA ART, the expectation that the distribution facility will play an important role in supporting the deployment and maintenance of the INSPIRA ART100 system, the Company's goal to introduce physicians and perfusionists to its technologies, that the distribution center will facilitate the potential commercialization of other future products, the belief that the agreement represents a crucial milestone in our efforts to introduce Inspira's innovative technologies to the market, the belief that the Company is well-positioned for the future launch of the INSPIRA ART and other products in its pipeline, the belief that combining Glo-Med's distribution network and capabilities with Med-Stat will create a fully vertically integrated business model and the belief that this structure will lead to success for the Company, Glo-Med and Med-Stat. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov.

Contact:

Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

MRK-ARS-118

Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/inspira-announces-establishment-of-distribution-facility-to-support-us-deployment-of-inspira--art100-302285959.html

SOURCE Inspira Technologies

FAQ

When will Inspira Technologies (IINN) deploy the INSPIRA ART100 in the US?

Inspira Technologies plans to deploy the INSPIRA ART100 in 2024 through their newly established distribution facility in Florida.

What regulatory approvals has Inspira Technologies (IINN) received for the INSPIRA ART100?

The INSPIRA ART100 has received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

What is the market size potential for Inspira Technologies' (IINN) INSPIRA ART device?

The INSPIRA ART targets a potential estimated market opportunity of $19 billion, aiming to serve 20 million acute respiratory failure patients annually.

Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares

NASDAQ:IINN

IINN Rankings

IINN Latest News

IINN Stock Data

24.05M
18.36M
8.88%
1.06%
0.52%
Medical Devices
Healthcare
Link
United States of America
Ra'anana